Pharma Bio Serv Inc (PBSV) 0.8800 $PBSV Pharma-Bio Serv

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharma Bio Serv Inc (PBSV) 0.8800 $PBSV

Pharma-Bio Serv to Present at 6th Annual LD Micro Invitational Conference on June 8th, 2016
ACCESSWIRE - Tue May 31, 7:30AM CDT
DORADO, PUERTO RICO / ACCESSWIRE / May 31, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that Victor Sanchez, CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 8th, 2016 at 11:30am PST, Track 2 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 8 and 9, 2016.

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2016
ACCESSWIRE - Wed Mar 16, 3:40PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / March 16, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues of $4.9 million for the quarter ended January 31, 2016, a decrease of approximately $1 million, or 17%, when compared to the same period last year. The revenue decrease is mainly attributable to a decline in projects in the Puerto Rico, United States and Europe consulting markets of $0.7, $0.5 and $0.2 million, respectively, partially offset by a gain in the Puerto Rico Lab operation of approximately $0.3 million. Other Company divisions sustained minor revenue gains/losses or remained constant, when compared to the same period last year.

Pharma-Bio Serv Announces Total Net Revenues of $23.4 Million and Net Income of $1.6 Million for the Year Ended October 31, 2015
ACCESSWIRE - Fri Jan 29, 4:13PM CST
DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced total net revenues of $23.4 million for the year ended October 31, 2015, a decrease of approximately $4.2 million, or 15.1%, when compared to last year. The revenue decrease is mainly attributable to a decline from projects in the United States and Europe consulting markets.

Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2015
ACCESSWIRE - Tue Nov 24, 3:30PM CST
DORADO, PUERTO RICO / ACCESSWIRE / November 24, 2015 / Pharma-Bio Serv, Inc. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that the Company will be a featured presenter at the 8th annual LD Micro Main Event Conference. Victor Sanchez, CEO will present Pharma-Bio Serv's business model and growth strategy at 4:30pm PST on December 2, 2015 in Track 5 at the Luxe Sunset Hotel in Los Angeles, CA.

Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2015
ACCESSWIRE - Mon Sep 14, 3:31PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues for the three and nine months ended July 31, 2015 of $6.2 and $17.5 million, respectively, a decrease of approximately $0.6 and $2.9 million, or 9.6% and 14.3%, respectively, when compared to the same periods last year. The revenue decrease is mainly attributable to declines in the United States and Europe consulting markets of $1.1 and $0.3 million and $4.1 and $0.8 million, for the three months and nine months ended July 31, 2015, as compared to the same periods last year, respectively, partially offset by gains in the Puerto Rico consulting business of approximately $0.8 and $2.0 million, respectively. Latin America projects, managed from Puerto Rico, contributed to Puerto Rico consulting gains in the amount of $0.2 and $1.2 million for the three and nine months ended July 31, 2015, when compared to the same periods last year, respectively.

Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2015
ACCESSWIRE - Mon Jun 15, 4:15PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / June 15, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues for the three and six months ended April 30, 2015 of $5.4 and $11.3 million, respectively, a decrease of approximately $1.1 and $2.3 million, or 17.2% and 16.6%, respectively, when compared to the same periods last year. The revenue decrease is mainly attributable to declines in the United States and Europe consulting markets of $1.4 and $0.2 million, and $2.9 and $0.5, for the three months and six months ended April 30, 2015, as compared to the same periods last year respectively, partially offset by gains in the Puerto Rico consulting business of $0.6 and $1.3 million, respectively. Latin America projects, managed from Puerto Rico, contributed to Puerto Rico consulting gains in the amount of $0.5 and $1.0 million for the three and six months periods ended April 30, 2015 when compared to the same periods last year, respectively.

Pharma-Bio Serv Announces Total Net Revenues of $27.6 Million and Net Income of $2.4 Million for the Year Ended October 31, 2014
ACCESSWIRE - Thu Jan 29, 5:17PM CST
DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced total net revenues of $27.6 million for the year ended October 31, 2014, a decrease of approximately $5.5 million, or 16.7%, when compared to the same period last year. The revenue decrease is mainly attributable to a decline from consulting projects in the United States and Europe.

Pharma-Bio Serv Appoints Víctor Sánchez as President and Chief Executive Officer Effective January 1, 2015
ACCESSWIRE - Tue Dec 02, 8:01AM CST
DORADO, PUERTO RICO / ACCESSWIRE / December 2, 2014 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, announced today that the Board of Directors has appointed Víctor Sánchez as President and Chief Executive Officer, effective January 1, 2015.
MRK: 55.89 (-1.61)

Pharma-Bio Serv Retains T.R. Winston & Company to Enhance Growth Opportunities Through Business Development, Mergers & Acquisitions, and to Review Strategic Alternatives
ACCESSWIRE - Mon Dec 01, 8:01AM CST
DORADO, PUERTO RICO / ACCESSWIRE / December 1, 2014 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, announced today that it has retained T.R. Winston & Company (T.R. Winston) in order to assist Pharma-Bio Serv in enhancing the Company's growth strategy through business development, and mergers and acquisitions.

Pharma-Bio Serv Signs Strategic Collaboration Agreement With Quality Technical Iberica, S.L.
Marketwired - Thu Oct 09, 3:05PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that it has signed a three-year strategic collaboration agreement with Quality Technical Iberica, S.L ("QTI", a Spain-based company specializing in Calibrations, Validation, HVAC and Clean Room Qualification services.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Brinker International Posts Solid Q1 2027 Earnings

Updated Category News Views 80

Strong Earnings Highlight a Winning Streak Brinker International, folks, has done it again. With the latest release of their first quarter fiscal 2027 results, it’s clear they’ve been hitting the right notes, especially at Chili’s. The numbers don't lie—trust me, I've seen my fair share of earnings calls, and this one's got meat on the bones. Let’s break it...

Continue Reading
E-Bike Demo Day Spurs New Jersey's Policy Insights

Updated Category News Views 79

Velotric Sets the Stage for E-Bike Insights The chatter over at Trenton has been electric—and I mean that literally. On October 29, Assemblywoman Tennille R. McCoy will open the gates of the New Jersey State House to host an E-Bike Demonstration and Education Day. The goal? To slap some sense into lawmakers' understanding of the buzzing e-bike market. Velotric, a major...

Continue Reading
Innovative Trial Targets Drug Resistance in Lung Cancer

Updated Category News Views 68

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Continue Reading
ReachWell Revamps Platform for Better Community Reach

Updated Category News Views 79

ReachWell's Fresh Approach: A New Era Begins Become the whisper in the wind reaching ears far and wide—enter the new ReachWell. Sounds lofty? Well, it's shooting for the stars here, folks. This isn’t just some tech upgrade. It’s a whole new brand identity and a refreshed sense of purpose. These guys have tossed everything back on the drawing board, unveiling a...

Continue Reading
H.R. 10549: Hope Charities Pushes for Pharmacy Freedom

Updated Category News Views 63

Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...

Continue Reading
Genefluence Launches Rapid UTI PCR Test at Chelsea Hospital

Updated Category News Views 49

There's a fresh breeze blowing through the dusty corridors of healthcare, shaking things up for the better. You see, Genefluence, the brainchild of Professor Chris Toumazou, isn't just throwing a bunch of tech jargon around—it's setting the stage for a much-needed shake-up in how we handle urinary tract infections (UTIs) and, believe me, it couldn’t have come sooner....

Continue Reading
Labcorp Lifts 2026 Guidance Amid Strong Q3 Performance

Updated Category News Views 119

Labcorp's Q3 Numbers Speak Loud and Clear Another quarter, another robust set of numbers for Labcorp (NYSE:LH). The company is strutting into the spotlight with third-quarter 2026 results that have investors nodding in approval. Revenue surged to $3.81 billion, marking a 6.9% increase from the prior year's $3.56 billion. And get this: adjusted EPS jumped 14.5%, clocking...

Continue Reading
7-Eleven Rolls Out Korean Flavors in Bold Menu Shift

Updated Category News Views 68

7-Eleven's New Global Menu Twist October 2026 sees 7-Eleven, Inc. whip out an intriguing move, venturing east with its new Flavors of Korea menu. They're not just changing the game in convenience store aisles; they're dancing to the beat of global flavors—a shake-up fit for the world's largest convenience retailer. Think about bodega basics getting a spicy Korean...

Continue Reading
AEP's $100B Power Plan: Investing in Tomorrow's Energy

Updated Category News Views 85

Electricity Powerhouse Unleashes Ambitious Plan If you thought American Electric Power (NASDAQ:AEP) was just cruising along, think again. This week, they rolled out an eye-popping $100 billion plan to supercharge their infrastructure and meet soaring electricity demands. It’s like they’re building the future of power right in front of our eyes. Third-quarter earnings...

Continue Reading
Hallmark's Holiday Magic: Cards, Ornaments, Joy

Updated Category News Views 205

Hallmark's Seasonal Bonanza: Cards, Gifts, and More It's that time again when Hallmark rolls out the holiday carpet, the red one you usually just see in front of fancy theaters. Greeting cards, gifts, Keepsake Ornaments, and those nostalgic holiday flicks on Hallmark Channel—it's a full-on festive fiesta. But it's not just about shoving a card in an envelope; it's about...

Continue Reading

Top 5 Most Recently Viewed Articles

Rgenta Therapeutics Presents Innovative Data on RGT-61159

Updated Category News Views 192

Rgenta Therapeutics Unveils Preclinical Data on RGT-61159 WOBURN, Mass. – Rgenta Therapeutics, a pioneering biotechnology firm focused on the development of small molecule drugs targeting RNA for cancer and neurological disorders, has made an exciting announcement regarding its lead program, RGT-61159. This promising small molecule inhibitor, which selectively targets...

Continue Reading
TriMas Packaging Showcases Innovations at Upcoming Trade Events

Updated Category News Views 122

TriMas Packaging's Participation in Major Trade Shows TriMas Packaging, a leading group under TriMas (NASDAQ: TRS), is thrilled to announce its involvement in two prominent trade exhibitions. At these events, the company will display its extensive range of innovative and eco-friendly dispensing and closure product solutions that have garnered attention in the industry....

Continue Reading
Understanding Apollo Global Management's Recent Market Trends

Updated Category News Views 109

Understanding Apollo Global Management's Recent Market Trends The market is currently witnessing a notable shift in investor sentiment towards Apollo Global Management (NYSE: APO). This trend is not only striking but worth examining closely for anyone interested in market movements. Recent tracking of options activity has highlighted an interesting wave of bullish...

Continue Reading
Capricor Faces Securities Fraud Lawsuit: Investor Action Key

Updated Category News Views 16

Investors Take the Stage in Capricor Securities Case Here's something that'll make any shareholder's pulse quicken: Capricor Therapeutics, Inc. (NASDAQ: CAPR) is caught in a whirlwind of legal drama, and it's no soap opera. Rather, it's a class action lawsuit, brought forth by the vigilant folks over at Schall, Brown & Schwartz LLP ('SBS'), aimed squarely at alleged...

Continue Reading
Broad Arrow Auctions Collects $14.5 Million in Sales Triumph

Updated Category News Views 333

Broad Arrow Auctions Kicks Off a Successful Year Broad Arrow Auctions, an esteemed arm of Hagerty, recently embarked on its 2025 auction calendar with a remarkable showcase—the Academy of Art University Collection Auction. Held at the university's museum facilities, this auction captured the attention of classic car enthusiasts and collectors alike. A Glance at the...

Continue Reading